BioCentury
ARTICLE | Company News

DBV, Centre d'Immunologie de Marseille-Luminy (CIML) deal

October 22, 2012 7:00 AM UTC

DBV partnered with the CIML to research the mechanism of action involved in DBV's epicutaneous immunotherapy (EPIT) method of treating allergies. The 18-month program will have three parts: study of cells involved in handling the food allergens; migration to the lymph nodes; and transmission of the antigenic information at the lymph node level. DBV said the research will include peanut and milk allergens. The work will be performed jointly, but DBV said it will own the rights to any IP from studies it commissions...